Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024)

Lexaria Bioscience's Current Deferred Revenue history spans 6 years, with the latest figure at $4963.0 for Q3 2024.

  • Quarterly results put Current Deferred Revenue at $4963.0 for Q3 2024, changed N/A from a year ago — trailing twelve months through Aug 2024 was $4963.0 (changed N/A YoY), and the annual figure for FY2024 was $4963.0, changed.
  • Current Deferred Revenue for Q3 2024 was $4963.0 at Lexaria Bioscience, up from $4275.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $44255.0 in Q3 2020 to a low of $1000.0 in Q1 2021.
  • The 4-year median for Current Deferred Revenue is $5606.5 (2020), against an average of $16040.5.